SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the Goldman Sachs 46th Annual Global Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Tuesday, June 10, 2025, at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) FORM 10-Q Delaware 98-154172 ...

Nautilus Biotechnology (NAUT) Q1 2025 Earnings Call April 29, 2025 01:27 PM ET Speaker0 Good day, and thank you Speaker1 for standing by. Welcome to the Nautilus First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To ...

Nautilus Biotechnology (NAUT) Q1 2025 Earnings Call April 29, 2025 08:30 AM ET Company Participants Ji-Yon Yi - Vice PresidentSujal Patel - Co-Founder, CEO & DirectorParag Mallick - Co-Founder, Chief Scientist & DirectorAnna Mowry - Chief Financial OfficerElizabeth Koslosky - Global Investment Research AssociateThomas VonDerVellen - Equity Research Associate Conference Call Participants Jason Lai - Analyst Operator Good day, and thank you for standing by. Welcome to the Nautilus First Quarter twenty twenty ...

"In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 2025 will be the year that researchers begin to apply the Nautilus ...

Exhibit 99.1 Nautilus Biotechnology Reports First Quarter 2025 Financial Results SEATTLE, WA, April 29, 2025 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single- molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechno ...

Core Viewpoint - Nautilus Biotechnology, Inc. is set to report its financial results for the first quarter of 2025 on April 29, 2025, before market opening [1]. Company Overview - Nautilus Biotechnology, Inc. is a development stage life sciences company headquartered in Seattle, Washington, with research and development operations in San Carlos, California [3]. - The company is focused on creating a platform technology aimed at quantifying and understanding the complexity of the proteome, with a mission to democratize access to proteomics and advance human health and medicine [3]. Upcoming Events - The management will host a conference call on April 29, 2025, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss the financial results, business developments, and future outlook [2]. - The live audio of the conference call will be accessible on the "Investors" section of the company's website [2].

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Will Ortmayer - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilu ...

Delivering on the Promise of the Proteome FEBRUARY 27, 2025 Safe harbor This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the protein analysis market; Nautilus Biotechnology's anticipated total addressable market; the performance, value and enabling nature of Nautilus Biotechnology's proteomics and proteoform analysis techn ...

Business Combination and Financial Overview - Nautilus Biotechnology completed a business combination on June 9, 2021, resulting in the issuance of 20,000,000 shares for gross proceeds of $200 million[24]. - The company incurred net losses of $70.8 million and $63.7 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $273.0 million as of December 31, 2024[207]. - The company expects to incur substantial losses and negative cash flows for the foreseeable future, despite anticipated cost-savings from workforce reductions[207]. - The company may need to raise additional capital to fund its development and commercialization plans[196]. Market Potential and Growth - The global proteomics market is estimated at approximately $27 billion annually as of 2022, with a projected growth to $55 billion by 2027, representing a CAGR of 15%[31]. - The proteomics market represents one of the largest untapped opportunities in biological sciences today, with substantial potential applications in various fields[53]. - Approximately 95% of FDA-approved drug targets are proteins, highlighting the critical importance of understanding the proteome in pharmacology[45]. - The company anticipates significant demand for proteomic data in preclinical and clinical drug development, enhancing understanding of drug interactions and resistance mechanisms[126]. Technology and Platform Development - Nautilus aims to develop a proteome analysis platform capable of identifying approximately 95% of proteins in a sample, significantly enhancing the characterization of the proteome[28]. - The Nautilus platform is expected to generate up to approximately 35 terabytes of digital protein data per run, utilizing advanced machine learning for data analysis[35]. - The platform is designed to measure billions of individual protein molecules simultaneously, achieving extreme sensitivity and a wide dynamic range[74]. - The Nautilus platform aims to democratize proteomics, with initial applications in precision medicine and a growth path into clinical diagnostics and machine-learning powered drug discovery[42]. Research Collaborations and Partnerships - The company has established research collaborations with major biopharma companies and academic institutions, including Genentech and Amgen, to validate its technology[32]. - The company has signed research collaboration agreements with Genentech, Amgen, and The University of Texas MD Anderson Cancer Center to explore the utility of its platform technology[148]. - The company plans to engage future customers through research collaborations to generate data and publications that highlight the value of single-molecule proteomics[144]. Commercialization Strategy - Nautilus plans a phased commercialization strategy, starting with partnerships and moving towards a broad commercial launch of its proteome analysis system[32]. - The company plans to commercialize the Nautilus platform through the sale of instrumentation, reagent consumables, and a SaaS analytics software[129]. - The go-to-market strategy includes three phases, focusing on building value propositions and leveraging partnerships to drive commercial momentum[143]. - The company anticipates that the Nautilus platform will facilitate large sample size studies, making previously impractical research feasible[116]. Competitive Landscape - The life sciences market is highly competitive, with major competitors including Thermo Fisher Scientific and Bruker Corporation, among others[153]. - The company believes it has significant competitive advantages due to its novel approach to proteomic technology and the unique capabilities of its platform[154]. Regulatory Environment - The FDA issued a final rule in May 2024 that phases out enforcement discretion for most laboratory-developed tests (LDTs), classifying in vitro diagnostics as medical devices under the Federal Food, Drug, and Cosmetic Act[164]. - International sales of medical devices will be subject to the IVD Medical Device Regulation (IVDR) in the EU, which aims to improve quality and safety standards for in vitro diagnostic medical devices[168]. - The company is subject to various federal and state laws regarding the collection and protection of health-related personal information, including the Health Insurance Portability and Accountability Act (HIPAA) and the California Consumer Privacy Act (CCPA)[171]. Challenges and Risks - The company may face significant delays in product development and commercialization due to the scientific and technical complexity of the Nautilus platform[211]. - The company has experienced difficulties with co-development partners in delivering component technologies on time, which could impact development timelines[209]. - The company has no experience in manufacturing its products at commercial scale, which could delay commercialization and result in lost revenue[220]. - The company may face increased compliance costs and potential liability due to evolving data privacy regulations, including the General Data Protection Regulation (GDPR) in the European Economic Area[172]. Intellectual Property and Innovation - The company has secured a strong intellectual property portfolio with numerous key patents since its inception in 2016[33]. - As of December 31, 2024, the company owned or held exclusive licenses to 31 issued U.S. patents and approximately 136 pending foreign patent applications, with patents expected to expire between 2026 and 2044[177]. - The technology aims to create a broad portfolio of affinity reagent probes through in-house development and strategic partnerships, enhancing its application range[110]. Employee and Organizational Structure - The company had 155 employees as of December 31, 2024, with over one-third holding doctorate degrees, and 110 engaged in research and development activities[187]. - The company is in the early stages of establishing a commercial organization focused on the Nautilus platform, requiring substantial financial resources for hiring and development[222].